|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Nant_Cell
none reported
|
|
gptkbp:advocacy
|
support groups
|
|
gptkbp:biotech_collaborations
|
research institutions
|
|
gptkbp:biotech_funding
|
public offerings
|
|
gptkbp:biotech_landscape
|
competitive environment
|
|
gptkbp:biotech_pipeline
|
drug candidates
|
|
gptkbp:biotech_research
|
translational medicine
|
|
gptkbp:business_model
|
gptkb:Cell
|
|
gptkbp:ceo
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:clinical_research_sites
|
hospitals
|
|
gptkbp:clinical_trial
|
gptkb:cancer_treatment
Phase 1
Phase 2
Phase 3
various cancer treatments
overall survival
progression-free survival
patient trials
safety profiles
biotech company
|
|
gptkbp:collaboration
|
academic institutions
|
|
gptkbp:collaborations
|
biopharmaceuticals
|
|
gptkbp:employees
|
approximately 100
|
|
gptkbp:focus
|
gptkb:immunotherapy
|
|
gptkbp:founded
|
gptkb:2015
|
|
gptkbp:founder
|
gptkb:Patrick_Soon-Shiong
|
|
gptkbp:funding
|
grants
|
|
gptkbp:has_advisory_board
|
experts
|
|
gptkbp:headcount
|
employees
|
|
gptkbp:headquarters
|
gptkb:Culver_City,_California
|
|
gptkbp:healthcare
|
cancer immunotherapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nant Kwest
|
|
gptkbp:innovation
|
cancer therapies
|
|
gptkbp:instruction_set
|
therapeutic candidates
|
|
gptkbp:investment
|
gptkb:venture_capital
biotech sector
|
|
gptkbp:is_a_platform_for
|
NK cell therapy
|
|
gptkbp:leadership
|
biotech executives
|
|
gptkbp:market
|
oncology
|
|
gptkbp:marketing_strategy
|
global expansion
innovation-driven
|
|
gptkbp:mission
|
transform cancer treatment
|
|
gptkbp:partnership
|
gptkb:Nant_Works
|
|
gptkbp:partnerships
|
pharmaceutical companies
various pharmaceutical companies
clinical collaborations
|
|
gptkbp:patient_population
|
cancer patients
|
|
gptkbp:publications
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
clinical data
|
|
gptkbp:research
|
cancer biology
|
|
gptkbp:research_and_development
|
biologics
|
|
gptkbp:research_areas
|
gptkb:NK-92_cells
immuno-oncology
novel therapies
immune modulation
|
|
gptkbp:research_focus
|
solid tumors
cancer immunotherapy
cell-based therapies
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
yes
|
|
gptkbp:stock_symbol
|
NK
|
|
gptkbp:technology
|
natural killer cells
natural killer cell therapy
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:treatment
|
treatment efficacy
|
|
gptkbp:vision
|
personalized medicine
|
|
gptkbp:website
|
www.nantkwest.com
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
gptkb:Takeda
|
|
gptkbp:bfsLayer
|
4
|